Journal of Antimicrobial Chemotherapy (2001) 48, 9-23
© 2001 The British Society for Antimicrobial Chemotherapy
Supplement |
Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin
CHU de Caen, Service de Microbiologie, Avenue Côte de Nacre, 14033 Caen cedex, France
Abstract
Antimicrobial resistance amongst common respiratory pathogens has increased worldwide at an alarming rate and now threatens the clinical usefulness of a number of antibacterial agents. A major concern is the selection of resistance in the community, which tends to parallel the (often inappropriate) overuse of such agents. Such problems highlight the need for new antibacterial agents that retain activity against bacterial strains resistant to existing agents, and have a low potential to select for resistance or induce cross-resistance. Telithromycin is the first of a new family of antibacterials—the ketolides—and has been designed specifically for the treatment of community-acquired respiratory tract infections (RTIs). Numerous in vitro studies confirm the potent activity of telithromycin against pathogens commonly implicated in community-acquired RTIs, irrespective of their ß-lactam, macrolide or fluoroquinolone susceptibility. Against pneumococci, for example, MICs were 
1 mg/L irrespective of penicillin susceptibility, with 
98% of macrolide-resistant strains inhibited at 0.5 mg/L, regardless of the underlying mechanism of resistance (including erm, mef and ribosomal L4 mutations). Against Haemophilus influenzae and Moraxella catarrhalis, including ß-lactamase-positive strains, telithromycin is at least as potent as azithromycin. In addition, telithromycin has a very low potential for selection of resistant isolates or induction of cross-resistance. Importantly, and unlike existing macrolides, telithromycin does not induce MLSB resistance, a finding explained by the presence of the innovative 3-keto group in its chemical structure. Telithromycin therefore represents an important addition to the therapeutic armamentarium in an era of increasing antimicrobial resistance, with an expected low likelihood of the development of resistance in clinical use.
Notes
* Tel: +33-2-31-06-45-72; Fax: +33-2-31-06-45-73; E-mail: leclercq-r{at}chu-caen.fr
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Brook and J. N. Hausfeld Effect of telithromycin and azithromycin on nasopharyngeal bacterial flora in patients with acute maxillary sinusitis. Arch Otolaryngol Head Neck Surg, April 1, 2006; 132(4): 442 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Farrell and D. Felmingham The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniae J. Antimicrob. Chemother., October 1, 2005; 56(4): 795 - 797. [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Novotny, L. Jakobsen, N. M. Andersen, J. Poehlsgaard, and S. Douthwaite Ketolide Antimicrobial Activity Persists after Disruption of Interactions with Domain II of 23S rRNA Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3677 - 3683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Goff Short-Duration Therapy for Respiratory Tract Infections Ann. Pharmacother., September 1, 2004; 38(9_suppl): S19 - S23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Pankuch, L. M. Kelly, G. Lin, A. Bryskier, C. Couturier, M. R. Jacobs, and P. C. Appelbaum Activities of a New Oral Streptogramin, XRP 2868, Compared to Those of Other Agents against Streptococcus pneumoniae and Haemophilus Species Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3270 - 3274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-C. Cremieux, C. Muller-Serieys, X. Panhard, F. Delatour, M. Tchimichkian, F. Mentre, and A. Andremont Emergence of Resistance in Normal Human Aerobic Commensal Flora during Telithromycin and Amoxicillin-Clavulanic Acid Treatments Antimicrob. Agents Chemother., June 1, 2003; 47(6): 2030 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Leclercq and P. Courvalin Resistance to Macrolides and Related Antibiotics in Streptococcus pneumoniae Antimicrob. Agents Chemother., September 1, 2002; 46(9): 2727 - 2734. [Full Text] [PDF]
|
|
|
|
|
|
D. E. Low, J. de Azavedo, K. Weiss, T. Mazzulli, M. Kuhn, D. Church, K. Forward, G. Zhanel, A. Simor, and A. McGeer Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000 Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1295 - 1301. [Abstract] [Full Text] [PDF]
|
|